🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Biogen Rises Ahead of Alzheimer's Drug Decision

Published 05/06/2021, 03:35 am
© Reuters.
BIIB
-
JEF
-

By Christiana Sciaudone

Investing.com -- Biogen (NASDAQ:BIIB)'s trading about 5% higher after Jefferies (NYSE:JEF) reiterated a buy rating ahead of potential approval of its Alzheimer's candidate drug. 

The Food and Drug Administration is scheduled to rule on the aducanumab biologic license application by June 7.

Analyst Michael Yee sees the probability of approval at 50% to 60%, higher than consensus of no more than 30%, StreetInsider reported. Oppenheimer sees equal probabilities of aducanumab receiving approval or facing rejection, Benzinga reported.

The shares are likely to move 21% higher if approved, 11% lower if not, Oppenheimer said, which estimates the risk-adjusted peak sales forecast for aducanumab at about $2.7 billion in 2030, according to Oppenheimer.

Aducanumab apparently slows the progression of Alzheimer's in people with early signs of cognitive impairment. It's been a bumpy ride for the drug, with the FDA saying it appears to be effective, followed by an outside panel of agency advisers saying more data was needed, Bloomberg reported.   

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.